Omeros Corp
Ouvert
SecteurSoins de santé
9.34 6.62
Résumé
Variation du prix de l'action
24h
Min
8.76
Max
9.6
Revenu | -35M 51M |
|---|---|
Ventes | 9.9M 9.9M |
P/E Moyenne du Secteur | 8.64 49.052 |
BPA | 0.977 |
Marge bénéficiaire | 518.033 |
Employés | 175 |
EBITDA | 12M -17M |
Recommandations | Achat |
|---|---|
Prévisions sur 12 Mois | +357.67% upside |
Prochains Résultats | 13 août 2026 |
|---|
Capitalisation Boursière | -323M 713M |
|---|---|
Ouverture précédente | 2.72 |
Clôture précédente | 9.34 |
Sentiment de l'Actualité
By Acuity
50%
50%
146 / 342 Classement par Healthcare
Omeros Corp Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Omeros Corp
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.